

PRIMARY ANTIBODY CARTRIDGE (PAC)

CD34

Monoclonal Rabbit, Anti-CD34
Clone EP88

REF 014-1148-150

Ready-to-Use ■ 60 Tests

INSTRUCTIONS FOR USE

PAGE 1 of 2

INTENDED USE

IVD For *in vitro* diagnostic use.

Monoclonal rabbit anti-CD34, clone EP88, is intended for laboratory use to identify the human endothelial cell marker molecule, CD34, by light microscopy in both normal and pathological human paraffin-embedded tissue. Tissue should be processed in neutral buffered formalin using immunohistochemical procedures.

Positive results aid in the classification of normal and abnormal cells/tissues, and serve as an adjunct to conventional histopathology. The clinical interpretation of any positive staining or its absence should be complemented by morphological and histological studies with proper controls. Evaluations should be made by a qualified individual in conjunction with the patient's clinical history and other diagnostic test results.

Refer to the Celerus Wave® RPD Operator's Manual for additional information about Materials Required but Not Provided; Storage; Staining Procedure; Troubleshooting; Interpretation of Staining; and General Limitations.

SUMMARY AND EXPLANATION

The CD34 molecule is a cell membrane glycoprotein found on certain lymphoid and myeloid hematopoietic progenitor cells and vascular endothelium. The CD34 antibody can be used to identify CD34 expression in a variety of neoplasias, including vascular tumors and acute lymphoblastic leukemias. In addition, CD34 aids in detection of gastrointestinal stromal tumors.

PRINCIPLE OF PROCEDURE

Immunohistochemistry is a multi-step process to identify specific cell markers within tissue biopsies or tumor specimens. The sequential steps include antigen retrieval (optional), antibody application, and antibody visualization followed by optional counter-staining. Specimens are then coverslipped and observed under light microscopy by trained personnel. Normally, multiple antibodies are tested to determine lineage and cell cycle markers. The Celerus Wave® RPD is an automated IHC system that produces stained tissue.

Refer to the Celerus Wave® RPD Operator's Manual for additional information about the staining procedure.

MATERIALS AND METHODS

Reagent Provided

CLONE	Ig CLASS	IMMUNOGEN
EP88	Rabbit IgG	A synthetic peptide corresponding to the C-terminus of human CD34 protein

READY-TO-USE IN PRIMARY ANTIBODY CARTRIDGE

Anti-CD34 is provided with sodium azide as a preservative, in a Primary Antibody Cartridge (PAC), a self-contained dispenser of reagents. Each PAC contains sufficient reagent to complete 60 stained slides. PACs must remain upright to avoid spilling. PAC must be primed before first use.

Refer to the Celerus Wave® RPD Operator's Manual for additional information about the Primary Antibody Cartridge.

SPECIFICITY

Human CD34 molecule.

PRECAUTIONS

For professional users.

Minimize microbial contamination of reagents or an increase in nonspecific staining may occur.

Proper handling procedures should be used.

A Material Safety Data Sheet is available upon request.

Sodium azide deposits in drainage pipes made of lead or copper can result in the formation of highly explosive metallic azides. To avoid such deposits in drainage pipes, sodium azide should be discarded in a large volume of running water.

Sodium azide in the concentration used is not classified as hazardous. The following are the appropriate Risk (R) and Safety (S) phrases.

R36	Irritating to eyes.
R43	May cause sensitization by skin contact.
S24	Avoid contact with skin.
S26	In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S35	This material and its container must be disposed of in a safe way.
S37/39	Wear suitable gloves and eye/face protection.
S46	If swallowed, seek medical advice immediately and show the product container or label.

WASTE DISPOSAL

Adhere to all local laws when disposing of the PAC.

PACKAGING DAMAGE

DO NOT USE this product if it is leaking, has leaked, has spilled, cannot be primed, or has visually apparent physical damage.



PRIMARY ANTIBODY CARTRIDGE (PAC)

CD34

Monoclonal Rabbit, Anti-CD34
Clone EP88

REF 014-1148-150

Ready-to-Use ■ 60 Tests

INSTRUCTIONS FOR USE

PAGE 2 of 2

MATERIALS REQUIRED BUT NOT PROVIDED

Celerus Wave® RPD Instrument.

Refer to the Celerus Wave® RPD Operator's Manual for additional information about Materials Required but Not Provided.

STORAGE AND HANDLING

Store at the temperature indicated on the product label. Do not freeze. This product is stable up to the expiration date on the product label. Do not use this product after the expiration date.

To ensure a valid staining assay, the use of positive and negative tissue controls is recommended.

SPECIMEN COLLECTION AND HANDLING

Formalin-fixed paraffin embedded (FFPE) tissues, frozen tissues, or smears are suitable for use. Wave RPD detection kits have been optimized for tissues fixed with 10% formalin.

Slides should be baked overnight at 37 °C, or at 60 °C for one hour.

Use standard histochemical techniques to deparaffinize processed slides. Place slides in the Wave RPD Slide Rack according to the staining grid provided by the instrument software. Avoid drying tissue specimen during this process. After all slides to be stained have been inserted and reagents mounted on the instrument, start the staining run.

When the staining run is complete, remove the slide rack, then slides. Coverslip slides and view under light microscopy.

PRODUCT-SPECIFIC LIMITATIONS

CD34 antibody, when used on the Wave RPD System, detects antigens that survive routine formalin fixation, tissue processing and sectioning. Users who deviate from the recommended test procedures are responsible for interpretation and validation of patient results.

RESULTS EXPECTED / PERFORMANCE CHARACTERISTICS

Normal Tissues

The antibody detects the endothelial cell marker, CD34, in the membrane of vascular endothelium in a variety of normal tissues.

Abnormal Tissues

The antibody stains the endothelium of a variety of neoplastic tissues.

REFERENCES

Nishio H, Tada J, Hashiyama M, Hirn J, Ingles-Esteve J, Suda T. MC7. CD34 workshop panel report. In: Kishimoto T, Kikutani H, von dem Borne AEG, Goyert SM, Mason DY, Miyasaka M, et al., editors. Leucocyte typing VI. White cell differentiation antigens. Proceedings of the 6th International Workshop and Conference; 1996 Nov 10-14; Kobe, Japan. New York, London: Garland Publishing Inc.; 1997. p. 974-76.

Civin CI, Trischmann TM, Fackler MJ, Bernstein ID, Bühring HJ, Campos L, et al. M7.1. Report on the CD34 cluster workshop. In: Knapp W, Dörken B, Gilks WR, Rieber EP, Schmidt RE, Stein H, et al., editors. Leucocyte typing IV. White cell differentiation antigens. Proceedings of the 4th International Workshop and Conference; 1989 Feb 21-25; Vienna, Austria, Oxford, New York, Tokyo; Oxford University Press; 1989. p. 818-25.

Civin CI, Strauss LC, Fackler MJ, Trischmann TM, Wiley JM, Loken MR. Posi-tive stem cell selection-basic science. Prog Clin Biol Res 1990;333:387-402.

Krause DS, Fackler MJ, Civin CI, May WS. CD34: structure, biology, and clinical utility (review). Blood 1996;87:1-13.

Campos L, Guyotat D, Archimbaud E, Devaux Y, Trelle D, Larese A, et al. Surface marker expression in adult acute myeloid leukaemia; correlations with initial characteristics, morphology and response to therapy. Dr J Haematol 1989;72:161-6.

Dercksen MW, Daams GM, de Haas M, von dem Borne AEG, dan der Schoot CE. M10.2 Characterization of the CD34 cluster. In: Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, et al., editors. Leucocyte typing V. White cell differentiation antigens. Proceedings of the 5th International Workshop and Conference; 1993 Nov 3-7; Boston, USA, Oxford, New York, Tokyo; Oxford University Press; 1995. p. 850-3.









Fina L, Molgaard HV, Robertson D, Bradley NJ, Monaghan P, Delia D, et al. Expression of the CD34 gene in vascular endothelial cells. Blood 1990;75(12):2417-2426.

Serke S, van Lessen A., Huhn D. Quantitative fluorescence flow cytometry; a comparison of the three techniques for direct and indirect immunofluorescence. Cytometry 1998;33:179-87.

Sutherland DR, Keating A. The CD34 antigen; structure, biology and potential clinical applications. J Hematol 1992;1:115-129, 1992

van de Rijn M, Hendrickson MR, Rouse RV. CD34 expression by gastrointestinal tract stromal tumors. Hum Pathol. 1994 Aug;25(8):766-71.

EXPLANATION OF SYMBOLS

REF Catalog Number	 Temperature Limitations	LOT Batch Code	 Sufficient for <n> Tests	 Harmful, Irritant	 Warning
IVD In Vitro Diagnostic Medical Device	 Use By	 European Conformity	EC REP EC Representative	 Manufacturer	 Refer to Instructions for Use

